

Supporting Information

Sai Ruan, Xiaobin Lin, Lihua Xie, Lili Lin, Xiaoming Feng and Xiaohua Liu*

Key Laboratory of Green Chemistry & Technology, Ministry of Education, College of
Chemistry, Sichuan University, Chengdu 610064, China.

E-mail: liuxh@scu.edu.cn


Table of Contents

1. General information.....	S2
2. Typical procedure for guanidines preparation.....	S2
3. Optimization of the reaction conditions.....	S3
4. Substrate scope of the products.....	S5
5. Typical procedure for the cascade reaction.....	S6
6. The analytical and spectral characterization data of the products.....	S6
7. NMR spectra.....	S24
8. X-ray crystal structure of the product 3aa	S51
9. Copies of the CD spectra of the products.....	S53
10. References.....	S65

1. General information

¹H NMR spectra were recorded on commercial instruments (400 MHz). Chemical shifts were reported in ppm from tetramethylsilane with the solvent resonance as the internal standard (CDCl_3 , $\delta = 7.26$), ($(\text{CD}_3)_2\text{SO}$, $\delta = 2.5$), (MeOD , $\delta = 2.64$), ($(\text{CD}_3)_2\text{CO}$, $\delta = 2.05$). Spectra were reported as follows: chemical shift (δ ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), coupling constants (Hz), integration and assignment. ¹³CNMR spectra were collected on commercial instruments (100 MHz) with complete proton decoupling. Chemical shifts are reported in ppm from the tetramethylsilane with the solvent resonance as internal standard (CDCl_3 , $\delta = 77.0$), ($(\text{CD}_3)_2\text{SO}$, $\delta = 39.5$), (MeOD , $\delta = 49.0$), ($(\text{CD}_3)_2\text{CO}$, $\delta = 206.3$, $\delta = 29.8$). Enantiomeric excesses (*ee*) were determined by UPC2 analysis using the corresponding commercial chiralpak column as stated in the experimental procedures at 35 °C. Optical rotations were reported as follows: $[\alpha]_D^{18}$ (*c*: g/100 mL, in solvent). HRMS was recorded on a commercial apparatus (ESI Source). All catalytic reactions were run in dried glassware. THF, toluene and diethyl ether (Et_2O) were distilled from sodium benzophenone ketyl. Ethyl acetate, CH_2Cl_2 was distilled over CaH_2 .

2. Typical procedure for guanidines preparation




A solution of sulfonyl chloride **B** (10 mmol) was slowly added to a stirred solution of diamine **A** (10 mmol), NEt_3 (11 mmol) in dichloromethane (25 mL). The resulting mixture was stirred for another 2 hours, washed twice with water (25 mL) and dried over Na_2SO_4 . The solvent was removed *in vacuo* to give a white solid **C**. To a solution of **D** in CH_2Cl_2 (40 mL) was added NEt_3 (11 mmol), isobutyl carbonochloride (11 mmol) at 0 °C under stirring. After 10 min, **C** was added. The reaction was allowed to warm to room temperature for another 2 hours. The mixture was washed with 1 N KHSO_4 solution, saturated NaHCO_3 solution, and brine, dried over anhydrous Na_2SO_4 and concentrated to get a white solid **E**. Then, TFA (10 mL) was added to the CH_2Cl_2 (10 mL) solution of **E**, and stirred until the reaction finished (1 h). The pH value of the mixture was brought into the range of 10–12 by the addition of 2 N NaOH solution. The aqueous phase was extracted with CH_2Cl_2 (3×30 mL). The


combined organic phase was washed with brine, dried over anhydrous Na_2SO_4 and concentrated and purified through flash chromatograph as a white solid **F** (70% yield).

*n*BuLi (2.4 M in *n*-hexane, 3.3 eq., 16.5 mmol) was injected into a solution of **F** (5.0 mmol) in THF (30 mL) dropwise over 10 mins under nitrogen atmosphere at -20°C with well stirring. After additional 10 mins, a solution of *N,N*-dicyclohexylcarbodiimide (1.2 eq., 6.0 mmol) in 10 mL of THF was added dropwise within 10 mins. The reaction was allowed to warm to room temperature and detected by TLC. After 12 h, the mixture was evaporated under reduced pressure to get rid of THF, and the pH value of the mixture was brought into the range of 0–1 by the addition of 3 M HCl. The aqueous phase was extracted with CH_2Cl_2 (3×10 mL). The combined organic phase was washed with 3M HCl in brine, dried over anhydrous Na_2SO_4 and evaporated in vacuum, and purified through flash chromatograph on silica gel to produce guanidinium salt **G**. The purified guanidinium salt **G** can be given through recrystallization in CH_2Cl_2 and ethyl acetate. Then, guanidinium salt **G** in CH_2Cl_2 (20 mL) was added 5 M NaOH (20 mL) and stirred until the basification finished (10 mins). The pH value of the mixture was kept in the range of 11–12. The aqueous phase was extracted with CH_2Cl_2 (5×20 mL). The combined organic phase was washed with 5 M NaOH, dried over anhydrous Na_2SO_4 and evaporated in vacuum. Finally, a white solid was obtained. Then it was dissolved in CH_2Cl_2 and filtration through Celite to remove the silicone gel, concentrate to get a kind of white foam (22% yield). For other catalysts, the synthesis method could be found in the literature.¹

3. Optimization of the reaction conditions

Table 1: Screening of guanidines^[a]






entry	cat	yield (%) ^[b]	dr ^[c]	ee (%) ^[d]
1	G-1	98	>19:1	47
2	G-2	94	>19:1	52
3	G-3	97	>19:1	41
4	G-4	95	>19:1	74
5	G-5	99	>19:1	85
6	G-6	99	>19:1	76
7	G-7	99	>19:1	75
8	G-8	99	>19:1	80
9	G-9	99	>19:1	82
10	G-10	99	>19:1	74
11	G-11	99	>20:1	79
12	G-12	81	8:1	36
13	G-13	84	12:1	17
14	G-14	77	5:1	13
15	G-15	88	14:1	58
16	G-16	81	5:1	50
17	G-17	85	6:1	46
18	BG-1	86	2.5:1	24/14
19	BG-1•HBAr^F₄	75	2:1	23/11

[a] Unless otherwise noted, the reactions were carried out with the catalyst (10 mol%), **1a** (0.10 mmol) and **2a** (0.12 mmol) in ethyl acetate (1.0 mL) at -30 °C for 24 h. [b] Isolated yield. [c] Determined by NMR analysis. [d] Determined by UPC2 analysis.


Table 2: Screening of the solvents^[a]



entry	solvent	yield (%) ^[b]	dr	ee (%) ^[c]
1	Toluene	72	>19:1	54
2	THF	99	>19:1	88
3	CH ₂ Cl ₂	94	>19:1	79
4	Et ₂ O	80	>19:1	77
5	CH ₃ CN	86	>19:1	65
6	Ethyl acetate	99	>19:1	85

[a] Unless otherwise noted, the reactions were carried out with **G-5** (10 mol%), **1a** (0.10 mmol) and **2a** (0.12 mmol) in solvent (1.0 mL) at -30 °C for 24 h. [b] Isolated yield. [c] Determined by NMR analysis. [d] Determined by UPC2 analysis.

Table 3: Screening of the temperature^[a]




entry	T (°C)	t (h)	yield (%) ^[b]	dr ^[c]	ee (%) ^[d]
1	-30	24	99	>19:1	88
2	-40	24	99	>19:1	91
3	-50	72	99	>19:1	93
4	-60	72	99	>19:1	95
5 ^[e]	-60	72	99	>19:1	93
6	-70	96	99	>19:1	96
7	-78	96	trace	—	—

[a] Unless otherwise noted, the reactions were carried out **G-5** (10 mol%), **1a** (0.10 mmol) and **2a** (0.12 mmol) in solvent (1.0 mL) at the indicated temperature. [b] Isolated yield. [c] Determined by NMR analysis. [d] Determined by UPC2 analysis. [e] **G-5** (5 mol%).

4. Substrate scope

Table 4: Substrate scope of (*E*)-2-(2-nitrovinyl) phenols **1**^[a]




entry	1: R¹	t (h)	yield (%) ^[b]	dr ^[c]	ee (%) ^[d]
1	1a: H	72	99 (3aa)	>19:1	95
2	1b: 4-F	72	99 (3ba)	>19:1	95
3	1c: 4-Cl	72	90 (3ca)	>19:1	95
4	1d: 4-Br	72	84 (3da)	>19:1	96
5	1e: 5-Me	72	80 (3ea)	>19:1	92
6	1f: 5-Cl	72	85 (3fa)	>19:1	92
7	1g: 5-OH, 6-Me	72	80 (3ga)	>19:1	96
8	1h: 6- F	72	83 (3ha)	>19:1	94
9	1i: 6-Cl	72	82 (3ia)	>19:1	91
10	1j: 6-Br	72	80 (3ja)	>19:1	91
11	1k: 6-Me	72	92 (3ka)	>19:1	95

12	1l: 6-MeO	72	99 (3la)	>19:1	92
13	1m: 6-EtO	72	95 (3ma)	>19:1	93
14	1n: 6- <i>t</i> -Bu	72	99 (3na)	>19:1	95

[a] Unless otherwise noted, the reactions were carried out **G-5** (10 mol%), **1a** (0.10 mmol) and **2a** (0.12 mmol) in solvent (1.0 mL) at the indicated temperature. [b] Isolated yield. [c] Determined by NMR analysis. [d] Determined by UPC2 analysis.

Table 5: Substrate scope of azlactones **2**^[a]



entry	2: R ² /R ³	t (h)	yield (%) ^[b]	dr ^[c]	ee (%) ^[d]
15	4-ClC ₆ H ₄ / Bn	48	87 (3ab)	>19:1	95
16	4-BrC ₆ H ₄ / Bn	48	87 (3ac)	>19:1	96
17	4-MeC ₆ H ₄ / Bn	48	99 (3ad)	>19:1	95
18	4-MeOC ₆ H ₄ / Bn	48	99 (3ae)	>19:1	95
19	4-EtC ₆ H ₄ / Bn	48	99 (3af)	>19:1	98
20	4-NCC ₆ H ₄ / Bn	72	63 (3ag)	>19:1	93
21	Ph / 4-ClC ₆ H ₄ CH ₂	48	99 (3ah)	>19:1	96
22	Ph / Me	24	94 (3ai)	>19:1	98
23	Ph / <i>i</i> -Bu	72	97 (3aj)	>19:1	97
24	Ph / CH ₂ CH ₂ Ph	72	97 (3ak)	>19:1	98
25	Ph / 3-Indolylmethyl	72	99 (3al)	>19:1	99


[a] Unless otherwise noted, the reactions were carried out **G-5** (10 mol%), **1a** (0.10 mmol) and **2a** (0.12 mmol) in solvent (1.0 mL) at the indicated temperature. [b] Isolated yield. [c] Determined by NMR analysis. [d] Determined by UPC2 analysis.

5. Typical procedure for the cascade Michael reaction


2-nitrovinylophenol **1** (0.10 mmol), azlactone **2** (1.2-2 equiv) and the catalyst **G-5** (7.5 mg, 10 mol%) were added into the test tube, followed by the addition of THF (1.0 mL). Then the mixture was stirred at -60 °C. After completion, the reaction mixture was purified by silica gel column chromatography (ethyl acetate/petroleum ether 1/4-1/2) to afford the desired products. Then the product was directed for UPC2 analysis.

6. The analytical and spectral characterization data of the product


N-(*(3R,4R)*-3-benzyl-4-(nitromethyl)-2-oxochroman-3-yl)benzamide (**3aa**)



(dd, $J = 13.2, 9.6$ Hz, 1H), 3.21 (d, $J = 14.4$ Hz, 1H), 3.03 (d, $J = 14.4$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 168.1, 165.9, 150.1, 133.3, 132.7, 132.3, 130.1, 130.1, 129.1, 128.8, 128.3, 127.0, 126.4, 125.5, 121.4, 116.9, 74.3, 60.5, 40.5, 35.6. HRMS (ESI-TOF) calcd for $\text{C}_{24}\text{H}_{20}\text{N}_2\text{O}_5\text{Na}^+ (\text{M}+\text{Na})^+$, m/z: 439.1270, observed: 439.1271.




	Retention Time	Area	% Area
1	3.619	5231842	49.91
2	4.531	5249890	50.09




	Retention Time	Area	% Area
1	3.559	6850779	97.50
2	4.493	175929	2.50

*N-((3*R*,4*R*)-3-benzyl-6-fluoro-4-(nitromethyl)-2-oxochroman-3-yl)benzamide (3ba)*


White solid, $[\alpha]^{18} = +44.5$ ($c: 0.27, \lambda = 405$ nm, CH_2Cl_2); Determined by UPC2 analysis [Daicel chiralcel OJ-3, scCO₂/PrOH = 80/20, 2 mL/min, $\lambda = 232.0$ nm, t (major) = 5.01 min, t (minor) = 6.16 min]; ^1H NMR (400 MHz, CDCl_3) δ 7.57 – 7.52 (m, 2H), 7.51 – 7.44 (m, 1H), 7.40 – 7.33 (m, 2H), 7.31 – 7.25 (m, 3H), 7.10 – 6.99 (m, 4H), 6.85 (dd, $J = 8.4, 2.4$ Hz, 1H), 6.46 (s, 1H), 5.17 (dd, $J = 13.6, 3.2$ Hz, 1H), 5.08 (d, $J = 8.8$ Hz, 1H), 4.84 (dd, $J = 13.2, 9.2$ Hz, 1H), 3.22 (d, $J = 14.4$ Hz, 1H), 3.04 (d, $J = 14.4$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 168.1, 165.5, 160.7, 158.2, 146.1, 133.0, 132.5, 132.2, 130.0, 129.2, 128.8, 128.4, 127.0, 123.2 ($J = 7.5$ Hz, 1C), 118.4 ($J = 8.5$ Hz, 1C), 118.3, 116.6 ($J = 23.2$ Hz, 1C), 113.5 ($J = 25.3$ Hz, 1C), 74.0, 60.3, 40.1, 36.1. HRMS (ESI-TOF) calcd for $\text{C}_{24}\text{H}_{19}\text{FN}_2\text{O}_5\text{Na}^+ (\text{M}+\text{Na})^+$, m/z: 457.1176, observed: 457.1179.



	Retention Time	Area	% Area
1	5.015	10606801	50.32
2	6.098	10472280	49.68



N-((3*R*,4*R*)-3-benzyl-6-oxochroman-3-




3ca


	Retention Time	Area	% Area
1	5.005	26296987	97.75
2	6.158	605124	2.25

chloro-4-(nitromethyl)-2-yl)benzamide (3ca)

White solid, $[\alpha]^{18} = +54.5$ ($c: 0.52, \lambda = 405 + 54\text{ nm}, \text{CH}_2\text{Cl}_2$); Determined by UPC2 analysis [Daicel chiralcel OJ-3, scCO₂/iPrOH = 70/30, 1.5 mL/min, $\lambda = 254$ nm, t (major) = 4.23 min, t (minor) = 4.80 min]; ¹H NMR (400 MHz, CDCl₃) δ 7.50 – 7.35 (m, 3H), 7.32 – 7.20 (m, 6H), 7.08 – 6.88 (m, 4H), 6.32 (s, 1H), 5.09 (dd, $J = 13.6, 3.2$ Hz, 1H), 4.96 (d, $J = 8.4$ Hz, 1H), 4.77 (dd, $J = 13.6, 9.6$ Hz, 1H), 3.18 (d, $J = 14.4$ Hz, 1H), 2.97 (d, $J = 14.4$ Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 168.0, 165.3, 148.6, 132.9, 132.5, 132.2, 130.6, 130.1, 130.0, 129.2, 128.8, 128.5, 127.0, 126.4, 123.2, 118.3, 73.9, 60.1, 40.0, 36.1. HRMS (ESI-TOF) calcd for C₂₄H₁₉ClN₂O₅Na⁺ (M+Na)⁺, m/z: 473.0880, 475.0851; observed: 473.0879, 475.0874.




	Retention Time	Area	% Area
1	4.258	3111263	49.93
2	4.784	3119541	50.07



	Retention Time	Area	% Area
1	4.231	7930074	97.46
2	4.802	206699	2.54


N-((3*R*,4*R*)-3-benzyl-6-bromo-4-(nitromethyl)-2-oxochroman-3-yl)benzamide (3da)

White solid, $[\alpha]^{18} = +56.9$ ($c: 0.58, \lambda = 405$ nm, CH₂Cl₂); Determined by UPC2 analysis [Daicel chiralcel OJ-3, scCO₂/iPrOH = 90/10, 2 mL/min, $\lambda = 224.0$ nm, t (major) = 25.68 min, t (minor) = 28.83 min]; ¹H NMR (400 MHz, CDCl₃) δ 7.57 – 7.42 (m, 4H), 7.41 – 7.27 (m, 5H), 7.22 (d, $J = 1.2$ Hz, 1H), 7.13 – 7.04 (m, 2H), 6.99 (d, $J = 8.8$ Hz, 1H), 6.38 (s, 1H), 5.16 (dd, $J = 13.6, 3.2$ Hz, 1H), 5.03 (d, $J = 7.6$ Hz, 1H), 4.84 (dd, $J = 13.6, 9.6$ Hz, 1H), 3.27 (d, $J = 14.4$ Hz, 1H), 3.05 (d, $J = 14.4$ Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 168.0, 165.3, 149.1, 133.0, 132.9, 132.5, 132.2, 130.0, 129.2, 129.2, 128.8, 128.4, 127.1, 123.6, 118.6, 118.0, 73.9, 60.2, 39.9, 36.3. HRMS




3da

(ESI-TOF) calcd for $[M+Na]^+$ $C_{24}H_{19}BrN_2O_5Na^+$, m/z: 517.0375, 519.0355; observed: 517.0374, 519.0358.




	Retention Time	Area	% Area
1	25.954	18457768	50.63
2	28.572	17999838	49.37




	Retention Time	Area	% Area
1	25.684	42702976	98.05
2	28.830	849785	1.95


N-(3*R*,4*R*)-3-benzyl-7-methyl-4-(nitromethyl)-2-oxochroman-3-yl)benzamide (3ea)



White solid, $[\alpha]^{18} = -44.8$ ($c: 0.21$, $\lambda = 405$ nm, CH_2Cl_2); Determined by UPC2 analysis [Daicel chiralcel OJ-3, scCO₂/MeOH = 80/20, 1.5 mL/min, $\lambda = 218$ nm, t (major) = 3.39 min, t (minor) = 4.43 min]; ¹H NMR (400 MHz, CDCl₃) δ 7.52 – 7.37 (m, 3H), 7.32 – 7.20 (m, 5H), 7.10 – 6.97 (m, 2H), 6.90 (t, $J = 8.4$ Hz, 3H), 6.30 (s, 1H), 5.14 (dd, $J = 12.4, 2.4$ Hz, 1H), 4.90 – 4.67 (m, 2H), 3.22 (d, $J = 14.4$ Hz, 1H), 3.05 (d, $J = 14.4$ Hz, 1H), 2.28 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 168.0, 166.2, 150.0, 140.7, 133.4, 132.8, 132.3, 130.1, 129.1, 128.8, 128.2, 127.0, 126.1, 118.2, 117.4, 74.5, 60.6, 40.4, 35.3, 21.2. HRMS (ESI-TOF) calcd for $C_{25}H_{22}N_2O_5Na^+$ ($M+Na$)⁺, m/z: 453.1426, observed: 453.1428.




	Retention Time	Area	% Area
1	3.352	3876064	49.97
2	4.360	3880195	50.03




	Retention Time	Area	% Area
1	3.387	23319041	95.80
2	4.433	1023041	4.20


N-((3*R*,4*R*)-3-benzyl-7-chloro-4-(nitromethyl)-2-oxochroman-3-yl)benzamide (3fa)




White solid, $[\alpha]^{18} = -25.7$ ($c: 0.68, \lambda = 405 \text{ nm, CH}_2\text{Cl}_2$); Determined by UPC2 analysis [Daicel chiralcel OJ-3, $\text{scCO}_2/\text{MeOH} = 80/20, 1.5 \text{ mL/min, } \lambda = 254 \text{ nm, t (major)} = 4.87 \text{ min, t (minor)} = 5.75 \text{ min}]; ^1\text{H NMR} (400 \text{ MHz, CDCl}_3) \delta 7.53 (\text{d}, J = 7.6 \text{ Hz, 2H}), 7.46 (\text{t}, J = 7.2 \text{ Hz, 2H}), 7.33 (\text{t}, J = 7.2 \text{ Hz, 2H}), 7.29 – 7.22 (\text{m, 4H}), 7.16 – 6.95 (\text{m, 5H}), 6.47 (\text{s, 1H}), 5.14 (\text{dd, } J = 13.6, 2.8 \text{ Hz, 1H}), 5.00 (\text{d, } J = 8.8 \text{ Hz, 1H}), 4.82 (\text{dd, } J = 13.2, 10.0 \text{ Hz, 1H}), 3.24 (\text{d, } J = 14.4 \text{ Hz, 1H}), 3.03 (\text{d, } J = 14.4 \text{ Hz, 1H}). ^{13}\text{C NMR} (100 \text{ MHz, CDCl}_3) \delta 168.1, 165.3, 150.5, 135.5, 132.9, 132.5, 132.3, 130.1, 129.2, 128.8, 128.4, 127.4, 127.0, 125.5, 120.0, 117.4, 74.2, 60.3, 39.9, 36.2. HRMS (ESI-TOF) calcd for $\text{C}_{24}\text{H}_{19}\text{ClN}_2\text{O}_5\text{Na}^+ (\text{M}+\text{Na})^+$, m/z: 473.0880, 475.0851; observed: 473.0882, 475.0875.$



	Retention Time	Area	% Area
1	4.879	1383060	50.03
2	5.712	1381222	49.97



N-((3*R*,4*R*)-3-benzyl-7-(nitromethyl)-2-yl)benzamide (3ga)




hydroxy-8-methyl-4-oxochroman-3-


White solid ($\lambda = 254 \text{ nm, CH}_2\text{Cl}_2$);

Determined by HPLC analysis [Daicel Chiralpak IA, *n*-hexane/ $\text{iPrOH} = 80/20, 1.5 \text{ mL/min, } \lambda = 254 \text{ nm, t (major)} = 11.99 \text{ min, t (minor)} = 16.59 \text{ min}]; ^1\text{H NMR} (400 \text{ MHz, MeOD}) \delta 7.46 (\text{dd, } J = 16.0, 7.6 \text{ Hz, 3H}), 7.35 (\text{t, } J = 7.6 \text{ Hz, 2H}), 7.28 – 7.18 (\text{m, 5H}), 6.72 (\text{d, } J = 8.4 \text{ Hz, 1H}), 6.51 (\text{d, } J = 8.4 \text{ Hz, 1H}), 5.28 (\text{dd, } J = 12.8, 3.2 \text{ Hz, 1H}), 4.67 (\text{t, } J = 11.2 \text{ Hz, 1H}), 4.37 (\text{s, 1H}), 3.59 (\text{d, } J = 14.4 \text{ Hz, 1H}), 3.15 (\text{d, } J = 14.4 \text{ Hz, 1H}), 2.02 (\text{s, 3H}). ^{13}\text{C NMR} (100 \text{ MHz, MeOD}) \delta 170.3, 168.3, 158.0, 151.1,$

135.8, 135.0 133.0, 131.7, 129.5, 129.5, 128.4, 126.6, 113.8, 113.0, 111.5, 76.9, 61.1, 42.1, 37.5, 8.4. HRMS (ESI-TOF) caled for $\mathbf{C}_{25}\mathbf{H}_{22}\mathbf{N}_2\mathbf{O}_6\mathbf{Na}^+ (\mathbf{M}+\mathbf{Na})^+$, m/z: 469.1376, observed: 469.1371.




	Retention Time	Area	% Area
1	11.927	16096645	49.64
2	15.972	16329890	50.36




	Retention Time	Area	% Area
1	11.988	21455763	98.14
2	16.588	406858	1.86

N-((3*R*,4*R*)-3-benzyl-8-fluoro-4-(nitromethyl)-2-oxochroman-3-yl)benzamide (3ha)




White solid, $[\alpha]^{18} = +20.3$ ($c: 0.48, \lambda = 405 \text{ nm}, \text{CH}_2\text{Cl}_2$); Determined by UPC2 analysis [Daicel chiralcel OD-3, scCO₂/PrOH = 85/15, 2 mL/min, $\lambda = 226 \text{ nm}$, t (major) = 8.56 min, t (minor) = 7.44 min]; ¹H NMR (400 MHz, CDCl₃) δ 7.54 – 7.46 (m, 2H), 7.40 (t, $J = 7.2 \text{ Hz}$, 1H), 7.27 (t, $J = 8.0 \text{ Hz}$, 1H), 7.23 – 7.16 (m, 3H), 7.13 – 6.96 (m, 4H), 6.78 (d, $J = 7.2 \text{ Hz}$, 1H), 6.43 (s, 1H), 5.18 – 5.01 (m, 2H), 4.82 (dd, $J = 13.6, 9.6 \text{ Hz}$, 1H), 3.16 (d, $J = 14.4 \text{ Hz}$, 1H), 2.97 (d, $J = 14.4 \text{ Hz}$, 1H).

¹³C NMR (100 MHz, CDCl₃) δ 168.1, 164.7, 149.8 ($J = 25.1 \text{ Hz}$, 1C), 138.1 ($J = 11.6 \text{ Hz}$, 1C). 133.0, 132.5, 132.1, 130.0, 129.9 ($J = 21.6 \text{ Hz}$, 1C), 129.1 ($J = 13.8 \text{ Hz}$, 1C), 128.8 ($J = 9.5 \text{ Hz}$, 1C), 128.5, 127.0, 125.6 ($J = 7.0 \text{ Hz}$, 1C), 124.0, 121.0, 117.3, 117.1, 74.1, 60.4, 40.2, 36.3. HRMS (ESI-TOF) caled for $\mathbf{C}_{24}\mathbf{H}_{19}\mathbf{FN}_2\mathbf{O}_5\mathbf{Na}^+ (\mathbf{M}+\mathbf{Na})^+$, m/z: 457.1176, observed: 457.1176.




	Retention Time	Area	% Area
1	7.247	17289978	50.13
2	8.539	17200754	49.87




	Retention Time	Area	% Area
1	7.443	619787	2.99
2	8.562	20125463	97.01


N-((3*R*,4*R*)-3-benzyl-8-chloro-4-(nitromethyl)-2-oxochroman-3-yl)benzamide (3ia).



White solid, $[\alpha]^{18} = -28.3$ ($c: 0.27, \lambda = 365 \text{ nm}, \text{CH}_2\text{Cl}_2$); Determined by UPC2 analysis [Daicel chiralcel OJ-3, $\text{scCO}_2/\text{iPrOH} = 80/20, 1.5 \text{ mL/min}$, $\lambda = 236 \text{ nm}$, t (major) = 10.18 min, t (minor) = 11.60 min]; ^1H NMR (400 MHz, CDCl_3) ^1H NMR (400 MHz, CDCl_3) δ 7.59 – 7.54 (m, 2H), 7.53 – 7.47 (m, 1H), 7.44 – 7.36 (m, 3H), 7.34 – 7.28 (m, 3H), 7.14 – 7.07 (m, 3H), 7.05 – 6.97 (m, 1H), 6.38 (s, 1H), 5.20 (dd, $J = 13.6, 3.2 \text{ Hz}$, 1H), 5.10 (d, $J = 9.6 \text{ Hz}$, 1H), 4.89 (dd, $J = 13.6, 9.6 \text{ Hz}$, 1H), 3.24 (d, $J = 14.4 \text{ Hz}$, 1H), 3.11 (d, $J = 14.4 \text{ Hz}$, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 168.1, 164.9, 146.1, 133.1, 132.5, 132.2, 130.9, 130.0, 129.2, 128.8, 128.5, 127.0, 125.7, 124.4, 123.4, 122.3, 74.1, 60.4, 40.6, 35.9. HRMS (ESI-TOF) calcd for $\text{C}_{24}\text{H}_{19}\text{ClN}_2\text{O}_5\text{Na}^+$ ($\text{M}+\text{Na}$) $^+$, m/z: 473.0880, 475.0851; observed: 473.0883, 475.0863.




	Retention Time	Area	% Area
1	10.073	10033002	50.66
2	11.528	9773066	49.34




	Retention Time	Area	% Area
1	10.117	23002669	95.67
2	11.603	1039861	4.33

N-((3*R*,4*R*)-3-benzyl-8-bromo-4-(nitromethyl)-2-oxochroman-3-yl)benzamide (3ja)




White solid, $[\alpha]^{18} = -32.7$ ($c: 0.62, \lambda = 405 \text{ nm}, \text{CH}_2\text{Cl}_2$); Determined by UPC2 analysis [Daicel chiralcel OJ-3, $\text{scCO}_2/\text{iPrOH} = 70/30, 1.5 \text{ mL/min}$, $\lambda = 254 \text{ nm}$, t (major) = 5.20 min, t (minor) = 5.97 min]; ^1H NMR (400 MHz, $(\text{CD}_3)_2\text{SO}$) δ 8.70 (s, 1H), 7.65 (d, $J = 7.6 \text{ Hz}$, 2H), 7.55 (t, $J = 7.6 \text{ Hz}$, 1H), 7.44 (d, $J = 7.6 \text{ Hz}$, 1H), 7.34 (m, 3H), 7.28 (m, 3H), 7.14 (m, 3H), 6.38 (s, 1H), 5.20 (dd, $J = 13.6, 3.2 \text{ Hz}$, 1H), 5.10 (d, $J = 9.6 \text{ Hz}$, 1H), 4.89 (dd, $J = 13.6, 9.6 \text{ Hz}$, 1H), 3.24 (d, $J = 14.4 \text{ Hz}$, 1H), 3.11 (d, $J = 14.4 \text{ Hz}$, 1H). ^{13}C NMR (100 MHz, $(\text{CD}_3)_2\text{SO}$) δ 168.1, 164.9, 146.1, 133.1, 132.5, 132.2, 130.9, 130.0, 129.2, 128.8, 128.5, 127.0, 125.7, 124.4, 123.4, 122.3, 74.1, 60.4, 40.6, 35.9. HRMS (ESI-TOF) calcd for $\text{C}_{24}\text{H}_{19}\text{BrN}_2\text{O}_5\text{Na}^+$ ($\text{M}+\text{Na}$) $^+$, m/z: 473.0880, 475.0851; observed: 473.0883, 475.0863.

Hz, 2H), 7.46 (t, J = 7.6 Hz, 2H), 7.28 – 7.14 (m, 5H), 7.12 – 7.00 (m, 2H), 5.54 (dd, J = 14.4, 2.8 Hz, 1H), 5.10 (t, J = 10.4 Hz, 1H), 4.69 (t, J = 8.4 Hz, 1H), 3.33 (d, J = 14.4 Hz, 1H), 3.23 (d, J = 14.4 Hz, 1H). ^{13}C NMR (100 MHz, $(\text{CD}_3)_2\text{SO}$) δ 166.7, 164.9, 147.0, 133.9, 133.1, 132.7, 131.9, 130.3, 128.3, 128.0, 127.4, 127.1, 125.4, 123.8, 108.9, 74.7, 59.5, 36.3. HRMS (ESI-TOF) calcd for $[\text{M}+\text{Na}]^+$ $\text{C}_{24}\text{H}_{19}\text{BrN}_2\text{O}_5\text{Na}^+$, m/z: 517.0375, 519.0355; observed: 517.0387, 519.0369.




	Retention Time	Area	% Area
1	6.074	3190549	50.33
2	5.290	3148165	49.67




	Retention Time	Area	% Area
1	5.198	4075029	95.44
2	5.965	194720	4.56

*N-(3*R*,4*R*)-3-benzyl-8-methyl-4-(nitromethyl)-2-oxochroman-3-yl)benzamide (3ka).*




White solid, $[\alpha]^{18} = -26.1$ (c : 0.66, λ = 405 nm, CH_2Cl_2); Determined by UPC2 analysis [Daicel chiralcel OJ-3, scCO₂/MeOH = 80/20, 1.5 mL/min, λ = 254 nm, t (major) = 3.20 min, t (minor) = 4.04 min]; ^1H NMR (400 MHz, CDCl_3) δ 7.59 – 7.54 (m, 2H), 7.53 – 7.47 (m, 1H), 7.44 – 7.36 (m, 3H), 7.34 – 7.28 (m, 3H), 7.14 – 7.07 (m, 3H), 7.05 – 6.97 (m, 1H), 6.38 (s, 1H), 5.20 (dd, J = 13.6, 3.2 Hz, 1H), 5.10 (d, J = 9.6 Hz, 1H), 4.89 (dd, J = 13.6, 9.6 Hz, 1H), 3.24 (d, J = 14.4 Hz, 1H), 3.11 (d, J = 14.4 Hz, 1H). ^{13}C

NMR (100 MHz, CDCl_3) δ 168.1, 164.9, 146.1, 133.1, 132.5, 132.2, 130.9, 130.0, 129.2, 128.8, 128.5, 127.0, 125.7, 124.4, 123.4, 122.3, 74.1, 60.4, 40.6, 35.9. HRMS (ESI-TOF) calcd for $\text{C}_{25}\text{H}_{22}\text{N}_2\text{O}_5\text{Na}^+ (\text{M}+\text{Na})^+$, m/z: 453.1426, observed: 453.1429.




	Retention Time	Area	% Area
1	3.142	3156252	49.98
2	3.981	3159388	50.02




	Retention Time	Area	% Area
1	3.196	4944001	97.62
2	4.039	120510	2.38


N-((3*R*,4*R*)-3-benzyl-8-methoxy-4-(nitromethyl)-2-oxochroman-3-yl)benzamide (3la)



White solid, $[\alpha]^{18} = -10.5$ ($c: 0.71, \lambda = 405$ nm, CH_2Cl_2); Determined by UPC2 analysis [Daicel chiralcel OJ-3, scCO₂/MeOH = 80/20, 1.5 mL/min, $\lambda = 254$ nm, t (major) = 4.19 min, t (minor) = 5.20 min]; ¹H NMR (400 MHz, CDCl₃) δ 7.56 (d, $J = 8.0$ Hz, 2H), 7.47 (t, $J = 7.2$ Hz, 1H), 7.36 (t, $J = 7.6$ Hz, 2H), 7.33 – 7.26 (m, 3H), 7.19 – 7.04 (m, 3H), 6.96 (d, $J = 8.4$ Hz, 1H), 6.68 (d, $J = 7.6$ Hz, 1H), 6.46 (s, 1H), 5.24 (dd, $J = 13.6, 3.2$ Hz, 1H), 5.06 (d, $J = 9.2$ Hz, 1H), 4.90 (dd, $J = 13.6, 9.6$ Hz, 1H), 3.90 (s, 3H), 3.27 (d, $J = 14.4$ Hz, 1H), 3.13 (d, $J = 14.4$ Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 168.1, 165.6, 147.6, 139.1, 133.4, 132.7, 132.3, 130.1, 129.1, 128.7, 128.2, 127.0, 125.6, 122.6, 117.2, 113.0, 74.3, 60.5, 56.3, 40.6, 35.4. HRMS (ESI-TOF) calcd for C₂₅H₂₂N₂O₆Na⁺ (M+Na)⁺, m/z: 469.1376, observed: 469.1373.




	Retention Time	Area	% Area
1	4.172	2518490	50.50
2	5.198	2468472	49.50




	Retention Time	Area	% Area
1	4.188	10445265	96.17
2	5.195	415795	3.83


N-((3*R*,4*R*)-3-benzyl-8-ethoxy-4-(nitromethyl)-2-oxochroman-3-yl)benzamide (3ma)



White solid, $[\alpha]^{18} = -16.3$ ($c: 0.64, \lambda = 405$ nm, CH_2Cl_2); Determined by UPC2 analysis [Daicel chiralcel OJ-3, scCO₂/MeOH = 80/20, 1.5 mL/min, $\lambda = 239$ nm, t (major) = 3.29 min, t (minor) = 4.26 min]; ¹H NMR (400 MHz, CDCl₃) δ 7.54 (d, $J = 8.0$ Hz, 2H), 7.44 (t, $J = 7.2$ Hz, 1H), 7.32 (t, $J = 7.6$ Hz, 2H), 7.25 (d, $J = 6.0$ Hz, 3H), 7.11 – 7.02 (m, 3H), 6.92 (d, $J = 8.4$ Hz, 1H), 6.64 (d, $J = 7.6$ Hz, 1H), 6.57 (d, $J = 15.6$ Hz, 1H), 5.18 (dd, $J = 13.6, 2.8$ Hz, 1H), 5.04 (d, $J = 8.8$ Hz, 1H), 4.87 (dd, $J = 13.6, 10.0$ Hz, 1H), 4.09 (q, $J = 7.2$ Hz, 2H), 3.26 (d, $J = 14.4$ Hz, 1H), 3.12 (d, $J = 14.4$ Hz, 1H), 1.41 (t, $J = 7.2$ Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 168.0, 165.7, 146.8, 139.5, 133.4, 132.8, 132.2, 130.1, 129.0, 128.7, 128.1, 127.1, 125.5, 122.7, 117.3, 114.4, 74.4, 65.1, 60.5, 40.5, 35.6, 14.7. HRMS (ESI-TOF) calcd for C₂₆H₂₄N₂O₆Na⁺ (M+Na)⁺, m/z: 483.1532, observed: 483.1536.




	Retention Time	Area	% Area
1	3.256	905866	50.60
2	4.210	884331	49.40




	Retention Time	Area	% Area
1	3.291	1105772	96.93
2	4.256	350354	3.07


**N-((3*R*,4*R*)-3-benzyl-8-
2-oxochroman-3-yl)benzamide (3na)**



White solid, $[\alpha]^{18} = -128.9$ (*c*: 0.48, $\lambda = 405$ nm, CH₂Cl₂); Determined by UPC2 analysis [Daicel chiralcel OJ-3, scCO₂/iPrOH = 70/30, 1.5 mL/min, $\lambda = 254$ nm, t (major) = 1.95 min, t (minor) = 2.89 min]; ¹H NMR (400 MHz, CDCl₃) δ 7.51 – 7.40 (m, 3H), 7.38 – 7.29 (m, 6H), 7.16 – 7.11 (m, 2H), 7.07 (t, *J* = 8.0 Hz, 1H), 6.95 (d, *J* = 7.6 Hz, 1H), 6.06 (s, 1H), 5.16 (dd, *J* = 13.2, 3.2 Hz, 1H), 4.80 (dd, *J* = 13.2, 10.4 Hz, 1H), 4.65 (s, 1H), 3.46 (d, *J* = 14.4 Hz, 1H), 3.09 (d, *J* = 14.4 Hz, 1H), 1.41 (s, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 167.6, 165.5, 149.2, 138.3, 133.2, 133.1, 132.3, 130.2, 129.1, 128.8, 128.1, 127.9, 126.9, 125.0, 124.8, 121.5, 74.7, 59.2, 41.0, 35.2, 35.0, 29.9. HRMS (ESI-TOF) calcd for C₂₈H₂₈N₂O₅Na⁺ (M+Na)⁺, m/z: 495.1896, observed: 495.1993.




	Retention Time	Area	% Area
1	1.959	4722127	50.09
2	2.831	4704480	49.91




	Retention Time	Area	% Area
1	1.954	10782399	97.54
2	2.894	272008	2.46


N-((3*R*,4*R*)-3-benzyl-4-(nitromethyl)-2-oxochroman-3-yl)-4-chlorobenzamide (3ab)



White solid, $[\alpha]_D^{18} = +14.9$ (*c*: 0.74, CH_2Cl_2); Determined by UPC2 analysis [Daicel chiralcel OJ-3, scCO₂/MeOH = 80/20, 1.5 mL/min, $\lambda = 254$ nm, *t* (major) = 5.40 min, *t* (minor) = 7.24 min]; ¹H NMR (400 MHz, CDCl_3) δ 7.35 (d, *J* = 8.4 Hz, 2H), 7.27 (t, *J* = 8.0 Hz, 1H), 7.19 (dd, *J* = 6.0, 3.2 Hz, 5H), 7.08 (t, *J* = 7.6 Hz, 1H), 7.05 – 6.93 (m, 4H), 6.42 (s, 1H), 5.10 (dd, *J* = 13.6, 3.6 Hz, 1H), 4.98 (d, *J* = 8.8 Hz, 1H), 4.81 (dd, *J* = 13.6, 9.2 Hz, 1H), 3.14 (d, *J* = 14.4 Hz, 1H), 2.97 (d, *J* = 14.4 Hz, 1H). ¹³C NMR (100 MHz, CDCl_3) δ 167.1, 165.8, 145.0, 138.7, 132.5, 131.6, 130.1, 130.0, 129.12, 129.0, 128.4, 128.3, 126.2, 125.5, 121.3, 116.9, 74.3, 60.7, 40.2, 35.8. HRMS (ESI-TOF) calcd for $\text{C}_{24}\text{H}_{19}\text{ClN}_2\text{O}_5\text{Na}^+$ (**M+Na**)⁺, *m/z*: 473.0880, 475.0851; observed: 473.0880, 475.0860.




	Retention Time	Area	% Area
1	5.457	3668391	50.15
2	7.252	3645882	49.85




N-((3*R*,4*R*)-3-benzyl-4-oxochroman-3-yl)-4-

(nitromethyl)-2-bromobenzamide (3ac)




White solid, $[\alpha]_D^{18} = +18.5$ (*c*: 0.80, CH_2Cl_2); Determined by UPC2 analysis [Daicel chiralcel OJ-3, scCO₂/MeOH = 80/20, 1.5 mL/min, $\lambda = 254$ nm, *t* (major) = 7.12 min, *t* (minor) = 9.80 min]; ¹H NMR (400 MHz, CDCl_3) δ 7.41 – 7.32 (m, 2H), 7.26 (d, *J* = 8.4

Hz, 2H), 7.22 – 7.17 (m, 4H), 7.13 – 6.96 (m, 5H), 6.44 (s, 1H), 5.09 (dd, J = 13.6, 3.2 Hz, 1H), 4.97 (d, J = 8.0 Hz, 1H), 4.80 (dd, J = 12.8, 10.0 Hz, 1H), 3.14 (d, J = 14.4 Hz, 1H), 2.97 (d, J = 14.4 Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 167.2, 165.8, 150.0, 132.5, 132.0, 132.0, 130.1, 130.0, 129.1, 128.6, 128.4, 127.2, 126.2, 125.6, 121.3, 116.9, 74.3, 60.6, 40.2, 35.8. HRMS (ESI-TOF) calcd for $[\text{M}+\text{Na}]^+$ $\text{C}_{24}\text{H}_{19}\text{BrN}_2\text{O}_5\text{Na}^+$, m/z: 517.0375, 519.0355; observed: 517.0375, 519.0380.




	Retention Time	Area	% Area
1	7.181	3786610	50.27
2	9.744	3745457	49.73




	Retention Time	Area	% Area
1	7.120	14250899	97.90
2	9.801	306299	2.10

N-(3*R*,4*R*)-3-benzyl-4-(nitromethyl)-2-oxochroman-3-yl)-4-methylbenzamide (3ad)

White solid, $[\alpha]^{18} = +19.8$ (c : 0.80, λ = 405 nm, CH_2Cl_2); Determined by UPC2 analysis [Daicel chiralcel OJ-3, scCO₂/MeOH = 80/20, 1.5 mL/min, λ = 254 nm, t (major) = 3.70 min, t (minor) = 4.59 min]; ^1H NMR (400 MHz, CDCl_3) δ 7.43 (d, J = 8.0 Hz, 2H), 7.39 – 7.27 (m, 4H), 7.20 – 7.05 (m, 7H), 6.33 (s, 1H), 5.22 (dd, J = 13.6, 2.8 Hz, 1H), 4.96 (d, J = 9.2 Hz, 1H), 4.86 (dd, J = 12.8, 10.0 Hz, 1H), 3.28 (d, J = 14.4 Hz, 1H), 3.11 (d, J = 14.4 Hz, 1H), 2.35 (s, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 168.0, 166.0, 150.2, 143.0, 132.8, 130.4, 130.1, 130.1, 129.4, 129.1, 128.2, 127.0, 126.4, 125.4, 121.4, 116.9, 74.4, 60.4, 40.5, 35.5, 21.5. HRMS (ESI-TOF) calcd for $\text{C}_{25}\text{H}_{22}\text{N}_2\text{O}_5\text{Na}^+$ ($\text{M}+\text{Na}$)⁺, m/z: 453.1426, observed: 453.1427.




	Retention Time	Area	% Area
1	3.740	2192509	50.33
2	4.601	2163406	49.67




	Retention Time	Area	% Area
1	3.700	16123064	97.61
2	4.589	395562	2.39


N-((3*R*,4*R*)-3-benzyl-4-oxochroman-3-yl)-4-methoxybenzamide (3ae) (nitromethyl)-2-



White solid, $[\alpha]^{18} = +39.0$ ($c: 0.70, \lambda = 405 \text{ nm}, \text{CH}_2\text{Cl}_2$); Determined by UPC2 analysis [Daicel chiralcel OJ-3, scCO₂/MeOH = 80/20, 1.5 mL/min, $\lambda = 254 \text{ nm}$, t (major) = 5.00 min, t (minor) = 6.27 min]; ¹H NMR (400 MHz, CDCl₃) δ 7.50 (d, $J = 8.8 \text{ Hz}$, 2H), 7.43 – 7.23 (m, 4H), 7.21 – 7.03 (m, 5H), 6.95 – 6.75 (m, 2H), 6.28 (s, 1H), 5.22 (dd, $J = 13.6, 3.2 \text{ Hz}$, 1H), 4.98 (d, $J = 8.4 \text{ Hz}$, 1H), 4.86 (dd, $J = 13.2, 10.0 \text{ Hz}$, 1H), 3.81 (s, 1H), 3.27 (d, $J = 14.4 \text{ Hz}$, 1H), 3.10 (d, $J = 14.4 \text{ Hz}$, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 167.5, 166.1, 162.9, 150.2, 132.8, 130.1, 129.1, 129.0, 128.3, 126.4, 125.4, 125.4, 121.5, 116.9, 114.0, 74.4, 60.4, 55.5, 40.5, 35.6. HRMS (ESI-TOF) calcd for C₂₅H₂₂N₂O₆Na⁺ (M+Na)⁺, m/z: 469.1376, observed: 469.1374.




	Retention Time	Area	% Area
1	5.081	1892455	50.00
2	6.550	1892191	50.00




	Retention Time	Area	% Area
1	4.998	17148322	97.77
2	6.272	390519	2.23

N-((3*R*,4*R*)-3-benzyl-4-(nitromethyl)-2-oxochroman-3-yl)-4-ethylbenzamide (3af)




White solid, $[\alpha]^{18} = +27.0$ ($c: 0.64, \lambda = 405 \text{ nm}, \text{CH}_2\text{Cl}_2$); Determined by UPC2 analysis [Daicel chiralcel OJ-3,

$\text{scCO}_2/\text{iPrOH} = 90/10$, 2 mL/min, $\lambda = 237.0$ nm, t (major) = 15.24 min, t (minor) = 18.84 min]; ^1H NMR (400 MHz, CDCl_3) δ 7.47 (d, $J = 8.4$ Hz, 2H), 7.40 – 7.28 (m, 4H), 7.23 – 7.04 (m, 7H), 6.36 (s, 1H), 5.22 (dd, $J = 13.2, 3.2$ Hz, 1H), 5.08 – 4.74 (m, 2H), 3.20 (dd, $J = 74.8, 14.4$ Hz, 2H), 2.80 – 2.49 (m, 2H), 1.21 (t, $J = 7.6$ Hz, 3H). ^{13}C NMR (100 Hz, CDCl_3) δ 1680, 1660, 150.2, 149.2, 132.8, 130.6, 130.1, 130.1, 129.1, 128.3, 127.1, 126.4, 125.4, 121.4, 116.9, 74.4, 60.3, 40.6, 35.5, 28.8, 15.2. HRMS (ESI-TOF) calcd for $\text{C}_{26}\text{H}_{24}\text{N}_2\text{O}_5\text{Na}^+ (\text{M}+\text{Na})^+$, m/z: 467.1583, observed: 467.1587.




	Retention Time	Area	% Area
1	15.350	30277677	49.92
2	18.518	30376356	50.08




	Retention Time	Area	% Area
1	15.236	49393675	98.98
2	18.839	510020	1.02

N-(3*R*,4*R*)-3-benzyl-4-oxochroman-3-yl)-4-cyanobenzamide (**3ag**) (nitromethyl)-2-

3ag White solid, $[\alpha]^{18} = +64.1$ ($c: 0.26$, $\lambda = 405$ nm, CH_2Cl_2); Determined by UPC2 analysis [Daicel chiralcel OJ-3, $\text{scCO}_2/\text{MeOH} = 80/20$, 1.5 mL/min, $\lambda = 254$ nm, t (major) = 4.82 min, t (minor) = 6.26 min]; ^1H NMR (400 MHz, $(\text{CD}_3)_2\text{SO}$) δ 8.88 (s, 1H), 7.95 (d, $J = 8.4$ Hz, 2H), 7.78 (d, $J = 8.0$ Hz, 2H), 7.31 (t, $J = 7.6$ Hz, 1H), 7.26 – 7.07 (m, 7H), 7.02 (d, $J = 8.0$ Hz, 1H), 5.52 (dd, $J = 14.0, 2.8$ Hz, 1H), 5.09 – 4.92 (t, $J = 10.8$ Hz, 1H), 4.65 (d, $J = 6.8$ Hz, 1H), 3.25 (dd, $J = 28.4, 14.4$ Hz, 2H). ^{13}C NMR (100 MHz, $(\text{CD}_3)_2\text{SO}$) δ 165.3, 165.1, 150.1, 137.1, 134.1, 132.4, 130.4, 129.5, 128.2, 128.1, 127.9, 127.1, 124.5, 121.6, 118.1, 115.8, 114.2, 74.9, 59.9, 36.0. HRMS (ESI-TOF) calcd for $\text{C}_{25}\text{H}_{19}\text{N}_3\text{O}_5\text{Na}^+ (\text{M}+\text{Na})^+$, m/z: 464.1222, observed: 464.1221.




	Retention Time	Area	% Area
1	4.939	465485	50.54
2	6.289	455517	49.46




	Retention Time	Area	% Area
1	4.819	12090792	96.80
2	6.254	399101	3.20


N-((3*R*,4*R*)-3-(4-methylbenzyl)-4-(nitromethyl)-2-oxochroman-3-yl)benzamide (3ah)



White solid, $[\alpha]^{18} = -78.3$ ($c: 0.58, \lambda = 405 \text{ nm}, \text{CH}_2\text{Cl}_2$); Determined by UPC2 analysis [Daicel chiralcel OJ-3, scCO₂/PrOH = 70/30, 2.0 mL/min, $\lambda = 254 \text{ nm}$, t (major) = 3.08 min, t (minor) = 4.10 min]; ¹H NMR (400 MHz, CDCl₃) δ 7.58 – 7.44 (m, 3H), 7.43 – 7.32 (m, 3H), 7.25 – 7.15 (m, 3H), 7.14 – 7.08 (m, 2H), 7.05 – 6.95 (m, 2H), 6.45 (s, 1H), 5.26 (q, $J = 9.2 \text{ Hz}$, 1H), 4.98 – 4.74 (m, 2H), 3.29 – 3.17 (dd, $J = 20.4, 14.4 \text{ Hz}$, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 168.1, 166.0, 150.0, 134.2, 133.2, 132.5, 131.3, 130.3, 129.2, 128.9, 127.0, 126.4, 125.6, 121.2, 117.0, 74.4, 60.7, 41.0, 34.5. HRMS (ESI-TOF) calcd for C₂₄H₁₉ClN₂O₅Na⁺ (M+Na)⁺, m/z: 473.0880, 475.0851; observed: 473.0882, 475.0872.




	Retention Time	Area	% Area
1	3.084	4804485	50.04
2	4.063	4797632	49.96




	Retention Time	Area	% Area
1	3.075	4138639	98.19
2	4.099	76371	1.81

N-((3*R*,4*R*)-3-methyl-4-(nitromethyl)-2-oxochroman-3-yl)benzamide (3ai)




White solid, $[\alpha]^{18} = -52.5$ ($c: 0.52, \lambda = 405 \text{ nm}, \text{MeOH}$); Determined by UPC2 analysis [Daicel chiralcel OJ-3, scCO₂/MeOH = 80/20, 1.5 mL/min, $\lambda = 232.0 \text{ nm}$, t (major) = 1.82 min, t (minor) = 2.33 min]; ¹H NMR (400 MHz, (CD₃)₂SO) δ 8.91 (s, 1H), 7.82 – 7.73 (m, 2H), 7.60 – 7.53 (m, 1H),

7.53– 7.44 (m, 2H), 7.44 – 7.35 (m, 3H), 7.33 – 7.07 (m, 3H), 5.24 (dd, J = 14.4, 8.0 Hz, 1H), 5.10 (dd, J = 14.4, 4.8 Hz, 1H), 4.93 (dd, J = 8.4, 4.4 Hz, 1H), 1.35 (s, 4H). ^{13}C NMR (100 MHz, $(\text{CD}_3)_2\text{SO}$) δ 167.5, 167.0, 149.9, 133.4, 131.8, 129.4, 128.2, 127.6, 126.7, 125.0, 121.9, 116.4, 74.2, 56.5, 18.1. HRMS (ESI-TOF) calcd for $\text{C}_{18}\text{H}_{16}\text{N}_2\text{O}_5\text{Na}^+ (\text{M}+\text{Na})^+$, m/z: 363.0956, observed: 363.0963.




	Retention Time	Area	% Area
1	1.828	712576	49.48
2	2.329	727630	50.52




	Retention Time	Area	% Area
1	1.816	4003826	99.14
2	2.309	34535	0.86

N-(3*R*,4*R*)-3-isobutyl-4-(nitromethyl)-2-oxochroman-3-yl)benzamide(3aj)

White solid, $[\alpha]^{18} = +19.4$ (c : 0.52, λ = 405 nm, CH_2Cl_2); Determined by UPC2 analysis [Daicel chiralcel OJ-3, scCO₂/MeOH = 85/15, 1.5 mL/min, λ = 238 nm, t (major) = 3.10 min, t (minor) = 2.69 min]; ^1H NMR (400 MHz, CDCl_3) δ 7.72 (d, J = 8.0 Hz, 2H), 7.50 (t, J = 7.2 Hz, 1H), 7.45 – 7.33 (m, 2H), 7.18 (t, J = 7.6 Hz, 1H), 7.10 (t, J = 6.8 Hz, 1H), 6.74 (s, 1H), 5.23 – 5.12 (m, 1H), 5.03 (dd, J = 13.6, 3.2 Hz, 1H), 4.85 (dd, J = 13.6, 9.2 Hz, 1H), 1.77 – 1.57 (m, 3H), 1.00 (d, J = 5.2 Hz, 3H), 0.81 (d, J = 5.2 Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 167.9, 166.3, 149.8, 133.5, 132.3, 129.8, 128.8, 127.0, 125.7, 125.5, 121.8, 117.0, 74.2, 60.7, 40.7, 38.1, 24.4, 23.9, 23.7. HRMS (ESI-TOF) calcd for $\text{C}_{21}\text{H}_{22}\text{N}_2\text{O}_5\text{Na}^+ (\text{M}+\text{Na})^+$, m/z: 405.1426, observed: 405.1427.




	Retention Time	Area	% Area
1	2.656	10841745	50.00
2	3.101	10841334	50.00




	Retention Time	Area	% Area
1	2.658	167314	1.33
2	3.100	12449065	98.67


N-((3*R*,4*R*)-4-(nitromethyl)-2-oxo-3-phenethylchroman-3-yl)benzamide (3ak)



White solid, $[\alpha]^{18} = -16.4$ ($c: 0.52, \lambda = 405 \text{ nm}, \text{CH}_2\text{Cl}_2$); Determined by UPC2 analysis [Daicel chiralcel OJ-3, scCO₂/MeOH = 80/20, 1.5 mL/min, $\lambda = 229 \text{ nm}$, t (major) = 9.27 min, t (minor) = 6.91 min]; ¹H NMR (400 MHz, CDCl₃) δ 7.48 – 7.42 (m, 1H), 7.41 – 7.37 (m, 2H), 7.37 – 7.26 (m, 4H), 7.25 – 7.13 (m, 5H), 7.10 (d, $J = 8.0 \text{ Hz}$, 2H), 6.61 (s, 1H), 5.17 (dd, $J = 9.2, 3.6 \text{ Hz}$, 1H), 5.00 (dd, $J = 13.6, 4.0 \text{ Hz}$, 1H), 4.87 (dd, $J = 13.6, 9.2 \text{ Hz}$, 1H), 2.83 – 2.61 (m, 2H), 2.31 – 2.18 (m, 1H), 2.17 – 2.08 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 167.9, 166.0, 149.9, 139.6, 132.9, 132.3, 129.9, 129.1, 128.6, 128.5, 127.0, 126.8, 125.9, 125.6, 121.5, 117.0, 74.2, 61.1, 40.4, 30.8, 29.9. HRMS (ESI-TOF) calcd for C₂₅H₂₂N₂O₅Na⁺ (M+Na)⁺, m/z: 453.1426, observed: 453.1427.




	Retention Time	Area	% Area
1	6.816	12765955	49.82
2	9.329	12857210	50.18




	Retention Time	Area	% Area
1	6.910	204320	0.93
2	9.267	21867126	99.07

N-((3*R*,4*R*)-3-((1*H*-indol-3-yl)methyl)-4-(nitromethyl)-2-oxochroman-3-yl)benzamide (3al)




White solid, $[\alpha]^{18} = -196.6$ ($c: 0.47, \lambda = 405 \text{ nm}, \text{CH}_3\text{COCH}_3$);


Determined by UPC2 analysis [Daicel chiralcel OJ-3, scCO₂/iPrOH = 70/30, 1.5 mL/min, $\lambda = 222.5$ nm, t (major) = 26.98 min, t (minor) = 21.90 min]; ¹H NMR (400 MHz, (CD₃)₂CO) δ 10.17 (s, 1H), 7.50 (s, 1H), 7.40 – 7.27 (m, 5H), 7.26 – 7.11 (m, 4H), 7.05 – 6.86 (m, 4H), 6.73 (t, $J = 7.6$ Hz, 1H), 5.66 – 5.35 (m, 1H), 4.97 – 4.59 (m, 2H), 3.65 (d, $J = 15.6$ Hz, 1H), 3.26 (d, $J = 15.6$ Hz, 1H). ¹³C NMR (100 MHz, (CD₃)₂CO) δ 168.0, 166.9, 152.1, 137.3, 134.8, 132.5, 130.4, 129.4, 129.2, 129.0, 128.2, 125.9, 125.2, 123.0, 122.4, 119.9, 119.3, 116.9, 112.3, 107.6, 76.2, 60.5, 41.3, 27.1. HRMS (ESI-TOF) calcd for C₂₆H₂₁N₃O₅Na⁺ (M+Na)⁺, m/z: 478.1379, observed: 478.1374.



	Retention Time	Area	% Area
1	21.245	6154771	50.04
2	26.560	6145168	49.96




	Retention Time	Area	% Area
1	21.895	60721	0.20
2	26.976	29758704	99.80




White solid, $[\alpha]_D^{18} = +36.3$ (*c*: 0.20, CH₂Cl₂); HRMS (ESI-TOF) calcd for C₄₃H₄₉F₂N₅O₃SH⁺ (M+H)⁺, m/z: 754.3602, observed: 754.3599. ¹H NMR (400 MHz, MeOD) δ 7.44 – 7.14 (m, 6H), 7.04 (dd, $J = 12.8, 5.2$ Hz, 7H), 6.93 (d, $J = 6.4$ Hz, 3H), 6.67 (t, $J = 8.8$ Hz, 1H), 5.07 (d, $J = 8.0$ Hz, 1H), 4.66 (d, $J = 14.0$ Hz, 1H), 4.58 (d, $J = 7.6$ Hz, 2H), 4.41 (d, $J = 14.0$ Hz, 1H), 3.54 – 3.39 (m, 2H), 3.12 (dd, $J = 15.2, 8.8$ Hz, 1H), 1.97 (s, 2H), 1.88 – 1.46 (m, 13H), 1.42 – 1.22 (m, 7H). ¹³C NMR (100 MHz, MeOD) δ 171.5, 161.7, 160.1, 135.6, 135.0, 129.4, 129.0, 128.8, 128.5, 128.3, 127.9, 126.7, 113.4, 113.1, 65.4, 64.3, 61.0, 60.2, 55.8, 50.2, 35.0, 34.9, 34.8, 34.0, 33.6, 26.8, 26.3, 26.1, 26.


7. NMR spectra


G-5








3aa






3ba








3ca




3da




3ea




3fa




3ga





3ha







3ia







3ja







3ka







3la







3ma







3na







3ab







3ac







3ad







3ae







3af







3ag







3ah







3ai







3aj







3ak





3al







8. X-ray crystal structure of the product 3aa



Identification code	f xm-ruan2
Empirical formula	C ₄₈ H ₄₀ N ₂ O ₅
Formula weight	832.84
Temperature/K	135
Crystal system	monoclinic
Space group	P21
a/Å	10.31419(17)
b/Å	19.2062(3)
c/Å	11.0205(2)
α/°	90
β/°	109.532(2)
γ/°	90
Volume/Å ³	2057.48(6)
Z	2
ρcalcg/cm ³	1.344
μ/mm ⁻¹	0.785
F(000)	872.0
Crystal size/mm ³	0.6 × 0.45 × 0.35
Radiation	Cu Kα (λ = 1.54184)
2Θ range for data collection/°	9.098 to 145.514
Index ranges	-12 ≤ h ≤ 9, -23 ≤ k ≤ 23, -13 ≤ l ≤ 13

Reflections collected	30369
Independent reflections	8035 [Rint = 0.0349, Rsigma = 0.0275]
Data/restraints/parameters	8035/1/559
Goodness-of-fit on F2	1.061
Final R indexes [$I \geq 2\sigma(I)$]	R1 = 0.0414, wR2 = 0.1079
Final R indexes [all data]	R1 = 0.0427, wR2 = 0.1097
Largest diff. peak/hole / e Å ⁻³	0.21/-0.30
Flack parameter	-0.07(6)





9. Copies of the CD spectra of the products 3





(R,R)-3aa (standard)





3aa





3ba

















3ea











3fa




































10. References

1. (a) Z. P. Yu, X. H. Liu, L. Zhou, L. L. Lin and X. M. Feng, *Angew. Chem. Int. Ed.*, 2009, **48**, 5195; (b) S. X. Dong, X. H. Liu, X. H. Chen, F. Mei, Y. L. Zhang, B. Gao, L. L. Lin and X. M. Feng, *J. Am. Chem. Soc.*, 2010, **132**, 10650; (c) S. X. Dong, X. H. Liu, Y. L. Zhang, L. L. Lin and X. M. Feng, *Org. Lett.*, 2011, **13**, 5060.